For Professionals
For Professionals
Amitriptyline: A safe, effective, well-tolerated option for second-line management of Irritable Bowel Syndrome
The ATLANTIS trial recruited 463 patients with persistent IBS symptoms from general practices and found that low-dose amitriptyline was found to be superior to placebo in reducing IBS symptoms such as abdominal pain and bloating, and improved satisfaction with bowel habit. Low-dose amitriptyline was found to be safe and well tolerated in all IBS subtypes. Patients self-titrated their dosage according to symptoms. This new evidence reinforces the importance of discussing it with patients who haven’t responded to first-line therapies.
Trial Results
Useful Links
- ATLANTIS trial main results
- ATLANTIS protocol paper
- NIHR Alert May 2024: Irritable bowel syndrome: low dose antidepressant improves symptoms.
- BMJ.com: Irritable bowel syndrome: low dose antidepressant improves symptoms.
- Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT.